Zoetis (ZTS) Cash from Investing Activities (2012 - 2026)

Zoetis' (ZTS) quarterly Cash from Investing Activities came in at -$87.0 million in Q1 2026, up 57.14% year-on-year from -$55.4 million in Q1 2025, and up 47.59% on a QoQ basis from -$166.0 million in Q4 2025.

Zoetis (ZTS) Cash from Investing Activities (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has 15 years of Cash from Investing Activities data on file, last reported at -$87.0 million in Q1 2026.

  • On a quarterly basis, Cash from Investing Activities rose 57.14% year-over-year to -$87.0 million in Q1 2026; TTM through Mar 2026 was -$632.0 million, a 63.31% decrease from a year earlier, with the FY2025 full-year figure at -$748.0 million, down 137.46% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at -$87.0 million, up from -$166.0 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for ZTS reached as high as $126.0 million in Q4 2024 and fell as low as -$438.0 million in Q4 2022.
  • Historically, Cash from Investing Activities has averaged -$165.3 million across 5 years, with a median of -$166.0 million in 2025.
  • Across the five-year window, Cash from Investing Activities jumped 160.0% in 2024 and tumbled 231.75% in 2025, its largest moves.
  • Year by year, Cash from Investing Activities stood at -$438.0 million in 2022, then surged by 52.05% to -$210.0 million in 2023, then soared by 160.0% to $126.0 million in 2024, then tumbled by 231.75% to -$166.0 million in 2025, then jumped by 47.59% to -$87.0 million in 2026.
  • Per Business Quant data, the three most recent Cash from Investing Activities figures were -$87.0 million in Q1 2026, -$166.0 million in Q4 2025, and -$160.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 229.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -87.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -369.95 Mn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 743.70 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 277.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn -506.20 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -60.00 Mn
10 Vireo Growth 10.51 Bn 10.36 Bn 59.30 Mn 8.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -87.00 Mn
Mar 31, 2026 -87.00 Mn
Dec 31, 2025 -166.00 Mn
Dec 31, 2025 -166.00 Mn
Sep 30, 2025 -160.00 Mn
Sep 30, 2025 -160.00 Mn
Jun 30, 2025 -219.00 Mn
Jun 30, 2025 -219.00 Mn
Mar 31, 2025 -203.00 Mn
Mar 31, 2025 -203.00 Mn
Dec 31, 2024 126.00 Mn
Dec 31, 2024 126.00 Mn
Sep 30, 2024 -178.00 Mn
Sep 30, 2024 -178.00 Mn
Jun 30, 2024 -132.00 Mn
Jun 30, 2024 -132.00 Mn
Mar 31, 2024 -131.00 Mn
Mar 31, 2024 -131.00 Mn
Dec 31, 2023 -210.00 Mn
Dec 31, 2023 -210.00 Mn